Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | AR | P10275 | 11/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxprenoate Potassium SCHEMBL6705633 | 1.00 | MEN1 (0.83) | MEN1KMT2ATDP1ARALDH1A1 | |
| SCHEMBL14861097 | 0.93 | AR (0.73) | MEN1KMT2ATDP1ARALDH1A1 | |
| SCHEMBL16146672 | 0.93 | AR (0.73) | MEN1KMT2ATDP1ARALDH1A1 | |
| SCHEMBL16146904 | 0.93 | AR (0.73) | MEN1KMT2ATDP1ARALDH1A1 | |
| SCHEMBL9799836 | 0.91 | MEN1 (0.81) | MEN1KMT2ATDP1ARALDH1A1 | |
| Oxprenoate Potassium SCHEMBL2734190 | 0.91 | TDP1 (1.00) | MEN1KMT2ATDP1ARALDH1A1 | |
| Oxprenoate Potassium SCHEMBL6706318 | 0.91 | TDP1 (1.00) | MEN1KMT2ATDP1ARALDH1A1 | |
| Oxprenoate Potassium SCHEMBL6706323 | 0.91 | TDP1 (1.00) | MEN1KMT2ATDP1ARALDH1A1 | |
| SCHEMBL11119304 | 0.90 | AR (0.72) | MEN1KMT2ATDP1ARALDH1A1 | |
| SCHEMBL11297403 | 0.89 | MEN1 (0.68) | MEN1KMT2ATDP1ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | AVENTIS PHARMA S.A. | 2004-12-02 | — | — | US | claimed |
| EP-0863760-B1 | USE OF ANTIMINERALOCORTICOID COMPOUNDS AGAINST DRUG WITHDRAWAL SYNDROME | AVENTIS PHARMA SA (FR) | 2001-12-05 | — | — | EP | claimed |
| EP-0018245-B1 | 7-ALKYL STEROID DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE IN MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1982-06-02 | — | — | EP | claimed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| WO-2010121814-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST | ONTOCHEM GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | AVENTIS PHARMA S.A. | 2004-12-02 | — | — | US | disclosed |
| US-6759399-B1 | USING SUCH AS GAMMA-LACTONE OF 10-ETHYNYL-17-HYDROXY-3-OXO-19-NOR-17-PREGNA-4,9(11)-DIENE-21-CARBOXYLIC ACID | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | disclosed |
| EP-0863760-B1 | USE OF ANTIMINERALOCORTICOID COMPOUNDS AGAINST DRUG WITHDRAWAL SYNDROME | AVENTIS PHARMA SA (FR) | 2001-12-05 | — | — | EP | disclosed |
| US-6147066-A | Use of antimineralocorticoid compounds against drug withdrawal syndrome | Roussel, Hoechst Marion (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | OPRM1, PNMT, SLC6A11 | MEN1 1425/4885KMT2A 1784/4885TDP1 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.